4685-50-1

Basic information

• Product Name: BenzeneMethanol, 3-Methoxy-4-Methyl-
• Synonyms: BenzeneMethanol, 3-Methoxy-4-Methyl-;(3-Methoxy-4-methylphenyl)methanol;3-Methoxy-4-methyl-benzenemethanol
• CAS NO: 4685-50-1
• Molecular Formula: C₉H₁₂O₂
• Molecular Weight: 152.19038
• Mol File: 4685-50-1.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: BenzeneMethanol, 3-Methoxy-4-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzeneMethanol, 3-Methoxy-4-Methyl-(4685-50-1)
• EPA Substance Registry System: BenzeneMethanol, 3-Methoxy-4-Methyl-(4685-50-1)

Safety Data

• Hazardous Substances Data: 4685-50-1(Hazardous Substances Data)

Usage

General Description

"Benzenemethanol, 3-methoxy-4-methyl-" is a compound with the chemical formula C9H12O2. It is also known by its IUPAC name 3-methoxy-4-methylbenzyl alcohol. This chemical is an aromatic alcohol, meaning it contains both a hydroxyl group (OH) and a benzene ring in its structure. It is commonly used as a fragrance ingredient in perfumes and cosmetics, and it also has potential applications in pharmaceuticals and organic synthesis. The compound is a clear, colorless liquid at room temperature and exhibits a sweet, floral odor. It is important to handle this chemical with care, as it can be harmful if ingested or inhaled, and can also cause skin and eye irritation.

Upstream product

• 62454-72-2 4-methyl-3-sulfobenzoic acid 
• 57295-30-4 3-hydroxy-4-methylbenzaldehyde 
• 586-30-1 3-hydroxy-4-methylbenzoic acid 
• 104901-43-1 methyl 3-bromo-4-methylbenzoate 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 24973-22-6 3-methoxy-4-methylbenzaldehyde 
• 3556-83-0 methyl 4-methyl-3-methoxybenzoate 

Downstream Products

• 3556-81-8 1-(3-methoxy-4-methylphenyl)ethan-1-one 
• 68233-86-3 (3-Methoxy-4-methylphenyl)-methylcarbinol 
• 323195-84-2 Ethyl (2E)-3-(3-methoxy-4-methylphenyl)but-2-enoate 
• 97329-88-9 (3S)-3-(3-Methoxy-4-methylphenyl)butan-2-ol 
• 97372-51-5 (S)-(+)-Xanthorrhizol methyl ether 
• 97372-52-6 (S)-(+)-Xanthorrhizol 
• 323195-90-0 (2E)-3-(3-Methoxy-4-methylphenyl)but-2-enal 
• 323195-87-5 (3S)-3-(3-Methoxy-4-methylphenyl)butyl iodide 
• 501371-37-5 2-methoxy-1-methyl-4-vinylbenzene 
• 122334-01-4 ethyl 4-(3-methoxy-4-methylphenyl)butanoate 
• 4685-51-2 4-(chloromethyl)-2-methoxy-1-methylbenzene 
• 1392422-13-7 (4-chlorophenyl)(3-methoxy-4-(pyrrolidin-1-ylmethyl)phenyl)methanamine 

Relevant articles and documents

Synthesis of Functionalized Indolines and Dihydrobenzofurans by Iron and Copper Catalyzed Aryl C-N and C-O Bond Formation

A simple and effective one-pot, two-step intramolecular aryl C-N and C-O bond forming process for the preparation of a wide range of benzo-fused heterocyclic scaffolds using iron and copper catalysis is described. Activated aryl rings were subjected to a highly regioselective, iron(III) triflimide-catalyzed iodination, followed by a copper(I)-catalyzed intramolecular N-or O-arylation step leading to indolines, dihydrobenzofurans, and six-membered analogues. The general applicability and functional group tolerance of this method were exemplified by the total synthesis of the neolignan natural product, (+)-obtusafuran. DFT calculations using Fukui functions were also performed, providing a molecular orbital rationale for the highly regioselective arene iodination process.

A novel anti-Alzheimer agent inhibiting oligomerization and fibriliation of beta-amyloid protects neuronal cell from Aβ-induced cytotoxicity

The present invention relates to development of a novel treatment agent for Alzheimerandprime;s disease, having ability of protecting neural cells and inhibiting fibrosis and oligomerization of beta-amyloid. A compound of the present invention is capable of, while maintaining therapeutic effects on Alzheimerandprime;s disease, recovering ability of directly inhibiting oligomerized and fibrous amyloid beta, which is inherent activities of existing curcumin, thereby being useful as a novel inhibitor.COPYRIGHT KIPO 2017

Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: Further structure-activity relationships, in vivo studies, and preliminary toxicity profiling

Despite recent progress in the fight against malaria, the emergence and spread of drug-resistant parasites remains a serious obstacle to the treatment of infections. We recently reported the development of a novel antimalarial drug that combines the 4-aminoquinoline pharmacophore of chloroquine with that of clotrimazole-based antimalarials. Here we describe the optimization of this class of hybrid drug through in-depth structure-activity relationship studies. Antiplasmodial properties and mode of action were characterized in vitro and in vivo, and interactions with the parasites 'chloroquine resistance transporter' were investigated in a Xenopus laevis oocyte expression system. These tests indicated that piperazine derivatives 4b and 4d may be suitable for coadministration with chloroquine against chloroquine-resistant parasites. The potential for metabolism of the drugs by cytochrome P450 was determined in silico, and the lead compounds were tested for toxicity and mutagenicity. A preliminary pharmacokinetic analysis undertaken in mice indicated that compound 4b has an optimal half-life.